PDCD1 and metabolic dysfunction-associated steatotic liver disease: Indeed, the frequency of the dysfunctional Siglec-7−CD57+PD-1+CD56dimpopulation was significantly increased in NAFLD patients even at the earliest stages of fibrosis (F0–2), but was unaffected by age, BMI, or metabolic complications such as hypertension, diabetes mellitus, and dyslipidemia (data not shown).